ClinicalTrials.gg
RecruitingNCT06793644cBPIUpdated Mar 19, 2026

Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients

An observational study in Fractures, Bone and Trauma Injury, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether an indocyanine green (ICG) fluorescence imaging system (cBPI) can be used to provide surgeons with information about bone health or bone blood flow. This will help surgeons better understand the healing potential of bone and relative risk of complication. This is important to help surgeons select the most appropriate treatment for severe traumatic injuries and infections.

02

Conditions studied

  • Fractures, Bone
  • Trauma Injury

Keywords

  • Immunofluorescence
  • Orthopaedic Trauma
  • Infection
03

In context

Fractures, Bone

723 studies on the registry are indexed under Fractures, Bone; 114 are open to participants now.

This study's planned enrollment of 10 is below the median of 130 across 239 observational studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 488 studies on the registry; 71 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 21 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 18 years of age or older who present with an open fracture or fracture related infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age or older.
  • Open extremity fracture, planning for management with external fixation, internal fixation or joint fusion.
  • Fracture Related Infection, planning for management with debridement and possible removal of hardware.
  • Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
  • Provision of .

Exclusion criteria

Exclusion Criteria:

  • Inability of patient to provide
  • Fracture of the hand.
  • Iodine allergy.
  • Burns at the fracture site.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Established SSI Fracture Cohort

    Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent

    Drug: Immunofluorescence Imaging

  • Open Fracture Cohort

    Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.

    Drug: Immunofluorescence Imaging

Interventions

  • DrugImmunofluorescence Imaging

    Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

06

What researchers measure

Primary outcomes

  1. Number of participants who undergo an unplanned fracture-related reoperation

    All unplanned reoperations will be documented using a specific case report form

    Time frame: 12 Months

  2. Number of participants who experience a post-procedure surgical site infection

    Post-procedure surgical site infection using Centers for Disease Control criteria will be documented at each follow-up

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793644
Collaborators
Dartmouth College
Responsible party
Ida Leah Gitajn (Section Chief Orthopaedics, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Jan 27, 2025
Start date
Jun 10, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Jon Mikael Anderson
Contact
jon.mikael.anderson@hitchcock.org
603-653-3306
Ida L Gitajn, MD
Contact
ida.l.gitajn@hitchcock.org
603-650-5000
Ida L Gitajn, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion